Mersana Therapeutics

Phase 1 study of emiltatug ledadotin (Emi-Le; XMT-1660) shows positive initial data in advanced cancers, with a tolerable safety profile and early efficacy signs. Emi-Le targets B7-H4, receiving FDA fast track for HER2-low/negative breast cancer. No grade 4/5 TRAEs reported; ORR of 23% in B7-H4–high tumors. Plans for 2025 include trial expansion and additional data presentation.

Charles Zhu maintains a Buy rating on Mersana Therapeutics with an $8.00 price target, citing promising clinical data for XMT-1660 (Emi-Le), its efficacy in heavily pretreated patients, a favorable safety profile, and FDA Fast Track Designations. Mersana's strong financial position further supports the rating.

Mersana Therapeutics announced positive Phase 1 trial results for emiltatug ledadotin (Emi-Le) in TNBC, showing efficacy and safety. The FDA granted Emi-Le Fast Track designation, boosting its market potential. Mersana focuses on ADCs for cancer, with platforms like Dolasynthen and Immunosynthen.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660, targeting advanced/metastatic breast cancer, including HER2 low/negative and TNBC patients. WHO approved 'Emi-Le' as XMT-1660's INN. The designation aims to expedite drug development for unmet medical needs, with potential benefits like Accelerated Approval.

Mersana Therapeutics' shares surged after receiving FDA fast-track designation for XMT-1660, a breast cancer treatment, and reporting positive Phase 1 study results. The drug targets advanced/metastatic breast cancer in HER2-low or negative patients, showing promise in early trials.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660 to treat advanced breast cancer in HER2-low or negative patients. WHO approved emiltatug ledadotin as XMT-1660's name. Positive Phase 1 data for emiltatug ledadotin, targeting B7-H4, was announced, showing promising safety and efficacy.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660, targeting advanced breast cancer, including HER2 low/negative and TNBC, post topoisomerase-1 inhibitor ADC treatment. WHO approved Emi-Le as XMT-1660's INN. The designation aims to expedite development and review for serious conditions with unmet needs.

Mersana Therapeutics received FDA Fast Track designation for XMT-1660 to treat advanced/metastatic breast cancer in HER2-low/negative patients, including TNBC, post topoisomerase-1 inhibitor ADC. WHO approved emiltatug ledadotin as XMT-1660's INN. Previously, Emi-Le got Fast Track for recurrent TNBC.

Mersana Therapeutics reported positive Phase 1 trial results for emiltatug ledadotin (Emi-Le), showing safety, tolerability, and efficacy in treating various cancers, including TNBC. With a 23% response rate in B7-H4 high tumors and no severe adverse events, Emi-Le advances to further trials at 67.4 mg/m2 every four weeks for TNBC patients previously treated with topo-1 ADC.

Mersana Therapeutics received an additional FDA Fast Track designation for XMT-1660, targeting advanced breast cancer, including HER2 low/negative and TNBC patients. The designation aims to expedite drug development for unmet medical needs. Mersana also announced WHO approval of the international name 'emiltatug ledadotin' for XMT-1660.